Viridian Therapeutics Inc (VRDN) has a current Price-to-Book (P/B) ratio of 8.03. Compared to its 3-year average P/B ratio of 4.11, the current P/B ratio is approximately 95.27% higher. Relative to its 5-year average P/B ratio of 4.44, the current P/B ratio is about 80.71% higher. Viridian Therapeutics Inc (VRDN) has a Forward Free Cash Flow (FCF) yield of approximately -11.14%. Compared to its 3-year average FCF yield of -17.27%, the current FCF yield is approximately -35.45% lower. Relative to its 5-year average FCF yield of -17.25%, the current FCF yield is about -35.38% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for VRDN competitors is 34.38, providing a benchmark for relative valuation. Viridian Therapeutics Inc Corp (VRDN.O) exhibits a P/S ratio of 62.53, which is 81.88% above the industry average. Given its robust revenue growth of 83.33%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of VRDN increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of VRDN in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is VRDN currently overvalued or undervalued?

What is Viridian Therapeutics Inc (VRDN) fair value?

VRDN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Viridian Therapeutics Inc (VRDN) is between to according to relative valuation method.

How does VRDN's valuation metrics compare to the industry average?

The average P/S ratio for VRDN's competitors is 34.38, providing a benchmark for relative valuation. Viridian Therapeutics Inc Corp (VRDN) exhibits a P/S ratio of 62.53, which is 81.88% above the industry average. Given its robust revenue growth of 83.33%, this premium appears sustainable.

What is the current P/B ratio for Viridian Therapeutics Inc (VRDN) as of Mar 04 2026?

As of Mar 04 2026, Viridian Therapeutics Inc (VRDN) has a P/B ratio of 8.03. This indicates that the market values VRDN at 8.03 times its book value.

What is the current FCF Yield for Viridian Therapeutics Inc (VRDN) as of Mar 04 2026?

As of Mar 04 2026, Viridian Therapeutics Inc (VRDN) has a FCF Yield of -11.14%. This means that for every dollar of Viridian Therapeutics Inc's market capitalization, the company generates -11.14 cents in free cash flow.

What is the current Forward P/E ratio for Viridian Therapeutics Inc (VRDN) as of Mar 04 2026?

As of Mar 04 2026, Viridian Therapeutics Inc (VRDN) has a Forward P/E ratio of -7.66. This means the market is willing to pay $-7.66 for every dollar of Viridian Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Viridian Therapeutics Inc (VRDN) as of Mar 04 2026?

As of Mar 04 2026, Viridian Therapeutics Inc (VRDN) has a Forward P/S ratio of 62.53. This means the market is valuing VRDN at $62.53 for every dollar of expected revenue over the next 12 months.

VRDN Valuation